Cabotegravir is somewhat novel -- not a recompounding of current therapy with different pharmacokinetics. Americans aren't going to develop an efficient approa

Cabotegravir is somewhat novel -- not a recompounding of current therapy with different pharmacokinetics. Americans aren't going to develop an efficient approach that is not highly encumbered because the FDA stacks the deck against approval of efficient solutions in favor of whatever makes the most total profit. So you'll see that sort of thing approved overseas and we'll get it (or not) in a decade or maybe never.